Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $48M (down 3.9% year over year) with net income of −$13M.
Q3 2026 key financials · XBRL
- Revenue
- $48M
- −3.9% YoY · +6.3% QoQ
- Net income
- −$13M
- +22.9% YoY · +20.8% QoQ
- Operating margin
- -23.9%
- Gross margin
- 79.5%
- EPS (diluted)
- −$0.19
- +26.9% YoY · +20.8% QoQ
Source: XBRL data from the TREACE MEDICAL CONCEPTS, INC. (TMCI) Q3 2026 10-Q on SEC EDGAR. USD.
TREACE MEDICAL CONCEPTS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $48.3M, down 3.9% YoY from $50.2M
- Gross margin 79.5% vs 79.1% YoY, supported by $0.7M IEEPA tariff refunds
- Worst performer: stocking distributor sales, down $5.1M YoY
- Operating cash flow use $0.7M, versus $7.9M in prior-year period
- Outlook: macroeconomic pressures, competition, pricing concessions, and lower-priced products remain headwinds
Risk Factors
- No material changes from 2025 Form 10-K risk factors
- Significant carried-forward risks remain unchanged, including regulatory compliance exposure
- Operating risks remain unchanged, including competition and procedure adoption
- Financial risks remain unchanged, including liquidity and capital requirements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TREACE MEDICAL CONCEPTS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.